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ABSTRACT  
 
Background and Objective: Patients with trigeminal neuralgia (TN) and multiple 
sclerosis (MS) are often treated with medications or a surgical procedure. However, 
there is little evidence that such treatments result in 50% pain reduction and 
improvement in quality of life. The aim of this systematic review is to evaluate the 
clinical effectiveness of treatments in patients with MS and trigeminal neuralgia. 
Databases and Data Treatment: We searched Medline, EMBASE, and the 
Cochrane Collaboration database from inception until October 2016. Two authors 
independently selected studies for inclusions, data extraction and bias assessment.  
Results: All studies were of low quality using the GRADE system. For medical 
management, ten studies were included of which one was a randomised control 
trials. Two studies were on the use of misopropol, unique to patients with MS. For 
surgical therapy, 26 studies with at least 10 patients and a minimum of two-year 
follow-up were included. All types of surgical procedures are reported and the results 
are poorer than for TN without MS with 50% having a recurrence by two years.  The 
main complications were sensory loss. Many patients had to undergo further 
procedures to become pain free and there were no agreed prognostic factors. 
Conclusions: There was insufficient evidence to support any one medical therapy 
and so earlier surgery may be preferable. A patient with TN and MS has therefore to 
make a decision based on low level evidence beginning with standard drug therapy 
and then choosing a surgical procedure.   
Key words: antiepileptic drugs , multiple sclerosis,  neurosurgery , systematic 
review,  trigeminal neuralgia  
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INTRODUCTION 
 
Unlike many other types of chronic pain, trigeminal neuralgia (TN), a severe 
unilateral episodic facial pain, can be managed both with medications or a variety of 
surgical procedures.  In the majority of patients the cause remains unknown but 
Harris 1 in 1950 noted a connection with multiple sclerosis (MS) and early 
epidemiological studies showed that there was a strong connection with MS and a 
20 fold higher prevalence of TN in this group. 2 
A recent systematic review of pain in MS suggested a prevalence of 3.8% (CI 2.0- 
6.0%) of TN and this is lower than headaches or neuropathic pain. 3 Another recent 
review suggested that over 30% of medications used by patients with MS are for 
pain. 4  
The clinical manifestations of TN in patients with MS are the same as for other forms 
of TN although there are reports of the attacks having some atypical features in that 
there is a more prolonged background pain. 5, 6, 7 However Sandell et al.,7  in their 
small cohort of 19 suggested that all patients initially have episodic pain and others 8 
also showed in their series that background pain was not related to presence or 
absence of demyelination in the trigeminal area. Mohammadi et al  9 found in their 
series that over time the pain became more atypical, larger number of divisions were 
involved and 6% became bilateral. It is generally thought that MS precedes TN but 
several series reported TN as a first symptom with intervals of between 10 and five 
years before another MS symptom. 10 9 11. No correlation between extent of MS 
plaques and clinical manifestations have been shown. 12, 13 There is a lack of data as 
to whether periods of remission occur in patients with MS.  Trigeminal reflexes 
including the blink reflex are abnormal in patients with MS and electrophysiological 
testing is highly accurate in distinguishing other forms of TN  from MS related TN. 6,14   
Cruccu et al 15 suggested that the plaques resulting in TN are in the pontine area and 
result in damage to the primary afferents.  The mechanism in MS related TN could 
be different and not the result of neurovascular compression although both 
mechanisms may be present in some patients. 14 It has been suggested that in MS 
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there is increased activity of T-cells leading to increased inflammatory activity in the 
plaques which makes them more susceptible to ephaptic nerve conduction. 6  
Antiepileptic drugs (AEDs) are the major drugs used for all types of pain in MS. 
Jawahar et al 16 in a systematic review have showed that for non TN pain this class 
of drug is effective and although side effects are reported they are demeaned 
tolerable.  It is important to note that currently none of the medications are curative 
and so they should be used only during periods of relapse and discontinued if 
surgery has resulted in pain relief.  
Two drugs are used more frequently in patients with TN and MS (pwTNMS) than in 
other TN patients are  baclofen and misoprostol . Baclofen is a GABAB agonist works 
whereas misoprostol is a prostaglandin-E 1- analogue which may reduce 
inflammatory activity in the plaques and so result in nerve stabilisation. 6  
The literature suggests that pwTNMS have greater problems with use of medications 
as they potentiate some of the MS symptoms and so higher more effective doses 
cannot be used.17 Ramsaransing et al., 18 reported on six patients with MS whose 
disability significantly increased when using carbamazepine.   Equally, surgical 
outcomes seem to be less satisfactory than in the other TN patients, possibly 
because the mechanism is different. However they do offer a period when 
medications can be withdrawn.  It has been suggested that microvascular 
decompression (MVD) should not be done as the cause of the TN is not 
compression of the nerve by a vessel but the demyelinating plaques on the 
trigeminal nerve. However, studies suggest that both can exist 7, 8, 10, 15,19 and a 
recent study suggests that neurovascular  decompression should be actively looked 
for in all patietns with TN.14 There is also evidence of demyelination in patients 
without clinically proven MS 8 ,20 Abhinav et al  8 have demonstrated that these 
patients can undergo successful partial sensory rhizotomy if no compressive vessels 
are found.   
In a fifty year old fit patient with TN and MS would treatment with medications or a 
surgical procedure result in 50% pain reduction and improved quality of life? In order 
to answer this question, a review of the literature on both pharmacological and 
surgical management of TN in pwTNMS was required. This could provide some 
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5 
guidance both to clinicians and patients as to the most effective management 
strategies. 
METHODOLOGY 
 Data sources and search strategy 
We performed a database search using Medline (in OvidSP), EMBASE and the 
Cochrane Collaboration database from their inception date until October 2016. 
Search terms were related to medical and surgical management of MS-TN patients 
please see table 1.). Previous searches of surgical treatments for TN were utilised to 
obtain reports which contained results on pwTNMS. 21  Only articles published in 
English were included and all abstracts were excluded. 
TABLE 1 HERE  
Study selection and data extraction 
Two reviewers (TB and JZ) independently screened the search results based on title, 
key words and abstract. 10% of the search results were then reviewed by a third 
reviewer ECB. All three reviewers met to compare the selection and resolve any 
differences by consensus.  
Of the surgical studies only those having 10 or more pwTNMS and a mean follow up 
of two years were included. In those which reported mixed cohorts, if the data on 
pwTNMS could not be extracted they were excluded. The surgical data was graded 
using the Surgical Trigeminal Neuralgia Score system 22 and if the scores were 
below 40% these were also rejected. 
Reviewers TB and JZ developed and completed the data extraction. Data was 
extracted into a medical table which compared and contrasted the drugs reported in 
the management for pwTNMS and another table was developed for the surgical 
data. Data were extracted on: 
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6 
(1) Author, date of publication, journal 
(2) Study design and clinical setting 
(3) Study population characteristics: basic demographics, TN and MS criteria of 
the patients, number of patients, number of patients with TN and MS, 
inclusion and exclusion criteria, study duration, duration of TN, duration of 
MS, onset order of TN and MS, interval between TN and MS, location of TN. 
(4) For drug management studies, the following data were extracted: drug 
prescribed, daily dosage, pain measure (Visual Analogue Scale), overall drug 
impact on pain, side effects. 
(5) For surgical studies, the follow data were extracted: type of surgery, duration 
of follow-up, lost to follow up, recurrence rate, recurrence interval, surgical 
complications. 
Data quality and synthesis 
All studies were open label and involved very few patients that met the inclusion 
criteria. The study duration varied significantly and the outcome measures were 
poorly reported. It was not possible to determine what constituted a 50% pain 
reduction in the medical trials. There is a high risk of publication bias due to the 
exclusion of studies in which the data on pwTNMS could not be extracted in those 
containing mixed cohorts. 
For medical management studies, data synthesis was not possible due to very small 
sample size. For surgical studies, data were synthesised by the type of surgical 
procedures.   
RESULTS  
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The initial search identified 540 records, and of these 78 was assessed as shown in 
Figure 1. Excluding review papers and studies that did not meet the inclusion criteria, 
10 medical therapy studies and 26 surgical therapy studies were included in this 
review.  A meta analysis was not possible due to the variability of the studies.  All 
studies yielded a low score on the GRADE system.  
Figure 1 HERE  
 Prevalence of pwTNMS 
Table 2 provides data on prevalence and demographic details of pwTNMS as found 
in both neurological and neurosurgical settings. The prevalence of TN among pwMS 
is 4.0%, which is consistent with 3.8% reported in the meta-analysis  by Foley et al.,. 
3
  Women predominate, 60.5%, with the average age of onset of TN being 45.4 
years which was significantly lower than that reported in other types of TN which is 
50-60 years. Of the 22 studies which reported the timing of TN in relation to MS 
10.5% had TN prior to MS and it could be over 10 years before another MS episode 
was reported.  Of the 24 studies reporting location 11% had bilateral symptoms 
compared to 3% in non MSTN.   De Simone 23 case control studies of 15 pwTNMS 
suggested that the clinical characteristics were the same as in other patients with TN 
and this was borne out by Cruccu et al.,15 and several other surgical studies. Cruccu 
al 15 suggested that MS starts later in those with TN.  
Table 2 HERE  
Medical therapies  
There were no systematic reviews, two reviews of general pain management in MS. : 
50,17
  There were 10 studies reported between 1970 and 2003 which included one 
RCT 51, one controlled trial  52,  two comparing different medications 53, 54 and one  
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8 
comparing an non MS TN group with a TNMS group 55. The rest were case reports 
and it was difficult to establish whether they were retrospective or prospective.  6,56, 
57,
 
58
    Five studies were from the same institution and no study had more than 18 
patients.   Only three studies provided details of the type of MS, two studies showed 
the criteria for diagnosis of TN. 59,52  Only one study used a VAS and recorded both 
intensity and number of attacks.  52 The majority of studies used a scale of 0-4 or just 
complete, partial and no response so it was not possible to dichotomize the results. 
No quality of life measures were used.   Additionally, the follow up (from 1 month to 
48 months) varied making it impossible to determine how many were lost to follow up 
or determine recurrence rate.  
The main results of the 10 pharmacological interventions including side effects are 
shown in table 3. 
Table 3 HERE   
Surgical management   
There are two reviews one  60 which reviews of all surgical procedures and Taich et 
al., 61 which  reviews  of all stereotactic radiosurgery procedures (SRS). Three 
studies dealt with multiple procedures of which Mohammadi et al., 9 series treated 96 
pwTNMS with 277 surgical procedures. Nine studies did not separate the MS data 
from their non MS TN so their data could not be used. Only 2 papers provided data 
on the type of MS. 9 ,10   Table 4 provides extra details of the selected  surgical 
procedures including details of outcome measures.   Table 5 summarises the 
outcomes by different surgical procedures and the weighted averages were obtained 
from the studies with available data.  
Tables 4 HERE  
Table 5 HERE  
Two  studies 7, ,10  reported on outcomes after MVD and one after partial sensory 
rhizotomy (PSR)   8  in a total of 77 pwTNMS.  After MVD , 73% of the patients had 
reported pain relief  whereas in the one PSR study it was 87% and the recurrence 
rate was 39%. after MVD and 21.7% after PSR.  Numbness occurred in 22/23 
patients after PSR and included one with  anaesthesia dolorosa compared to 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
Zakrzewska  
 
 
 
9 
numbness only in  2/105 in the MVD group.  Impaired hearing was noted in two 
patients after MVD..  
A total of 180 pwTNMS had undergone SRS procedures in six studies.  9, 38,47, 49, 61,62  
The average age of 60 years was significantly higher  than those undergone 
MVD/PSR procedures (52 years). 83.6% of the patients had pain relief after surgery 
but 51.1% had experienced recurrence during the follow-up period. Facial 
numbness, sensory loss and paraesthesia were reported in 11.7% of patients. Eight 
studies reported on use of percutaneous glycerol rhizotomy (PGR) in a total of 299 
pwTNMS whose average age was 51 years.  9,11,26,38, 42,63,64, 65 The average follow-
up was 42 months, 77.3% of the patients had good pain relief after the procedure 
while 53.4% had recurrences during the follow-up period. Of those patients who 
experienced a recurrence, the median recurrence time was 20.3 months, which was 
significantly shorter than those patients undergone SRS procedure (30.4 months). 
A total of 74 pwTNMS had undergone balloon microcompression (BC) 9, 37,39,66  and 
58 radiofrequency thermocoagulation (RFT)  12, 27, 29, 67 86.4% of those who had BC 
and 97.8% of those who had RFT had reported good pain relief. However, those who 
had BC reported the highest recurrence rate of 67.0% while those who had RFT 
reported the lowest recurrence rate of 27.5%.  
From studies using Kaplan Meier methodology it was possible to determine the 
probability of recurrence over a period of 5 years (Figure 2). This was the same 
method as previously used to assess probability of recurrence in non-MS  TN.68 All 
procedures reported that by two and half years, 50% of pwTNMS were likely to have 
had a recurrence and those studies which provided comparative data with non MS 
TN, showed better outcomes for the latter.  
The only none destructive procedure was MVD, a major neurosurgical procedure of 
which there are few studies. Whereas destructive (ablative) procedures, whether at 
the root entry zone or the Gasserian ganglion level were frequently reported.  
Figure 2 HERE   
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Recommendations for management  
Due to the lack of data it is difficult to advise how the presented patient should be 
managed. No pharmacological treatments can be advised specifically for pwTNMS 
so the same medical management can be used as  for non-MS TN i.e. 
carbamazepine or oxcarbazepine as first line  with second line drugs being 
lamotrigine, baclofen, gabapentin and pregablin.  69 70 Patients need to be given 
careful instructions about use of medications i.e. beginning the drugs slowly with  low 
doses and gradually increasing them and this can be done with the help of  pain 
diaries.    This approach would help to reduce side effects and potential 
exacerbations of existing MS symptoms.  Monotherapy is encouraged but 
polytherapy can be introduced to gain better control as Solaro et al.,71 showed.  
Patients need to be aware that flare ups can occur and they need to develop a 
strategy for how these can be dealt with by increasing the medication for a while. 
Conversely if a remission is reported in that patients indicate that they have no pain 
the drugs can be tapered down and stopped until the next flare up.  We have shown 
that support from psychologists and clinical nurse specialists with knowledge of 
these drugs can be extremely helpful (poster at International Association for the 
Study of Pain Congress 2016) and Douglas et al.,72  also showed that patients with 
MS who had a better biopsychosocial approach to their pain reported better 
outcomes.  
If pain control is poor then surgical options need to be considered but it is not 
possible to provide recommendations as to when this should occur nor is there any 
data to compare pharmacological versus surgical outcomes.  Although MVD does 
give poorer results in pwTNMS and a higher risk of complication there may be a 
place for it in those few with no plaques on the trigeminal nerve and with clear 
neurovascular compression( NVC)  on MRI although Abhinav et al’s 8 study 
suggested that the other option is to do a partial sensory rhizotomy. There are many 
more studies reporting other ablative procedures which are relatively easy to perform 
and carry less risk. They gave similar results in that by 2½ years 50% will have a 
recurrence. Repeat surgery does increase the risk of sensory changes. 
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DISCUSSION  
TN is common in pwMS. It can occur before MS and many present with classical 
symptoms 23 but  in pwTNMS up to 89% have abnormal trigeminal reflexes as 
compared to 3% in  idiopathic TN.15  The evidence for pharmacological management 
of TN is based on , open label studies with very small numbers and a high risk of 
bias. Only the DMKG 52 study group, defined inclusion criteria and measured 
outcome measures.  It is likely that the studies included a heterogeneous group of 
patients  both from the MS aspect and also TN as criteria used for diagnosis were 
only provided in one study.52  Most of the recruited patients had become non 
responsive to conventional medications but there was no indication as to what 
proportion they constituted.  There was scare data on length of time medications  
were used for , whether slow escalation occurred or whether drugs were stopped 
due to remissions. It has been suggested that pwTNMS are more likely to have side 
effects but in these studies the converse was found and this is not in agreement from 
other TN literature which shows that most patients have side effects. 73 Tiredness  
and ataxia are common side effects and can lead to further disability in patients with 
MS.   
Only oxcarbazepine has not been reported in pwTNMS and there were only two 
cases of pregablin use.. 74 The data on misoprostol cannot be generalised to other 
pwTNMS as the studies contained intractable cases with short follow up.  .   
There is thus an urgent need for RCTs which avoid use of placebos or active 
controls. An enhancement withdrawal enriched randomised control trial may be 
applicable and has been used in other TN trials.75 More robust outcome measures 
are needed that measure not only pain relief and reduction of paroxysms but also 
quality of life and its impact on MS using the EDSS.  A more systematic approach to 
side effects is needed to determine if tolerability is reduced in this group. A natural 
history of TN in pwTNMS is required to compare with non-MS  TN to determine if 
there are true differences as De Simone  et al 23 suggested that there are none. With 
improved imaging more patients may have MS than previously reported and TN 
could be the first symptom.  It is important to establish if pain increases during 
relapses of MS or whether it evolves over the course of MS and is linked to type of 
MS. This could be done using novel methodology  such as trials within cohorts.76  
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Within the surgical data there are no RCTs or controlled trials. The majority of data is 
retrospective with a high risk of bias.22  In a small sub group of  pwTNMS who have 
clear compression Truini et al ., 14  suggest  that MVD  should be considered  
although it needs to be noted that at present the results are poorer than in non MS 
TN so further data is required.  Other ablative procedures give poorer outcomes in 
pwTNMS than those with non MS  TN when the same methodology is used 68, 77 but 
they do provide up to two years pain relief without medication. RCTs comparing the 
varying ablative procedures should be possible and would provide much needed 
data. 38  
There is increased evidence that shared decision making increases patients 
satisfaction but significant challenges arise when the evidence is of low quality , 
conflicting, unavailable or not relevant to the patient. Epstein  & Gramling 78, and 
Politi et al.,79 among others suggestion ways of dealing with these problems which 
include  exploring values  and preferences and engaging in patient centred 
communication which is based on  a supportive relationship.  Patients, therefore 
need time and consultations jointly with physicians and neurosurgeons to determine 
what may be the best option for them at any particular time. In a study in which 
patients with TN where asked about their preferences for treatment surgical options 
were preferred to medical ones but the evidence on which the patients made their 
decisions  were based on  low quality evidence. 80  
CONCLUSIONS 
 In view of the lack of any high quality evidence it remains impossible to provide a 
pwTNMS such as the one described here with a definitive treatment plan. Both 
pharmacological and surgical treatments provide some pain relief but for shorter 
periods than on other TN patients.  More high quality studies are required.  
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Figure 1 Flow chart of the search process  
Figure 2 The  probability of a recurrence after a surgical procedure in patients 
with MS and trigeminal neuralgia. 
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Table 1   MS-TN Search Strategy 
MEDLINE SEARCH No. of RESULTS 
1. Multiple Sclerosis.mp.or exp Multiple 
Sclerosis/  
63615 
2.  MS.mp. [mp=title, abstract, original 
title, name of substance word, subject 
heading word, keyword heading word, 
protocol supplementary concept word, 
rare disease supplementary concept 
word, unique identifier] 
240108 
3. disseminated sclerosis.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
613 
4. encephalomyelitis disseminata.mp. 
[mp=title, abstract, original title, name 
of substance word, subject heading 
word, keyword heading word, protocol 
64 
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supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
5.  1 OR 2 OR 3 OR 4 275154 
6. Trigeminal Neuralgia/ 5957 
7. trigemin* neuralg*.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
7075 
8. (tic doloureux or TN).mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
9144 
9. TGN.mp. [mp=title, abstract, original 
title, name of substance word, subject 
heading word, keyword heading word, 
2157 
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protocol supplementary concept word, 
rare disease supplementary concept 
word, unique identifier] 
10.  facial pain.mp. [mp=title, abstract, 
original title, name of substance word, 
subject heading word, keyword heading 
word, protocol supplementary concept 
word, rare disease supplementary 
concept word, unique identifier] 
7341 
11. prosopalgia.mp. [mp=title, abstract, 
original title, name of substance word, 
subject heading word, keyword heading 
word, protocol supplementary concept 
word, rare disease supplementary 
concept word, unique identifier] 
16 
12.  fothergill's disease.mp. [mp=title, 
abstract, original title, name of 
substance word, subject heading word, 
keyword heading word, protocol 
supplementary concept word, rare 
disease supplementary concept word, 
unique identifier] 
2 
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13.  6 or 7 or 8 or 9 or 10 or 11 or 12 24122 
14.  5 and 13 540 
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Table 2 Prevalence and demographics of trigeminal neuralgia in patients with MS from neurology and neurosurgery studies.  
First Author year  TN& MS Clinical setting and  
overall number 
TN & MS % Male Female Age onset  
TN mean* 
Number 
TN first 
Mean interval between 
MS and TN in years 
Bilateral 
Abhinav8 2012 23 neurosurgery 
 
6 17 50±11 0 
 
0 
Antic24 2009 8 neurosurgery 
 
6 2 41 
   Ariai25 2013 10 neurosurgery 350 3 5 5 49 
   Bender26 2013  63 neurosurgery 822 8 46 29 52 12 NR 9 
Berk27 2003 13 neurosurgery 86 15 3 10 49 2 NR 
 Brett28 1982 8 neurosurgery 
 
6 2 53 0 
 
0 
Brisman29 1987 16 neurosurgery 219 7 3 13 45 
  
5 
Broggi10 2004 35 neurosurgery 
 
16 19 45 2 NR 3 
Chakravorty30 1966 10 neurology 124 8 4 6 51 0 
 
0 
Cheng31 2005 11 neurosurgery 
 
2      9 59±7 
  
3 
Cruccu15 2009 50 MS neuropathic pain  139 
 
18 32 43±11 15 10 4 
de Simone23 2005 15 neurology case control 13 MS 
   
43±10.5 
  
0 
Eldridge19 2003 9 neurosurgery 469 2 3 6 47 0 
 
0 
Eriksson32 2002 5 neurology MS 255 2 
      Hooge13 1995 35 MS  clinic 1882 2 11 24 51 5 11.8 5 
Huang33 2002 7 neurosurgery 50 
 
1 6 46 0 
 
0 
Jensen5 1982 22 neurology  900 2 10 12 50 3 12 7 
Kanpolat12 2000 17 neurosurgery 1672 1 11 6 42 2 NR 1 
Katusic34 1990  3 neurology 75 4 0 3 
 
0 
  Kondziolka35 1994 53 neurosurgery 594 9 18 35 56 (median) 
  
2 
Linderoth11 1989 23 neurosurgery 300 8 9 14 48 2 5-10 (range) 4 
Lummel36 2014 12 neuroradiology 
 
3 9 46 5 15 0 
Martin37 2015 17 neurosurgery 80 15 4 13 53 0 
  Mathieu38 2012 45 neurosurgery 
 
21 24 52 0 
 
0 
Mohammad9 2013 96 neurosurgery 
 
38 58 50 (median) 10 10 (median) 10 
Montano39 2012 21 neurosurgery 
 
10 11 47 6 13.8 0 
Moulin40 1988 7 neurology MS 159 4 
      Osterberg41 2005  18 neurology  MS 429 5 5 13 49 1 19 2 
Pickett42 2005 53 neurosurgery MS clinic 277 19 
  
50 0 
  Putzki43 2009 31 MS clinic 675 6 
  
41-80 (range) 
   Rogers44 2002 15 neurosurgery 240 6 5 10 
    Rushton45 1965 35 neurology 1735 2 13 22 
   
4 
Solaro46 2004 36 neurology MS 364 2 7 29 48 
   Tuleasca47 2014 43 neurosurgery 723 8 23 20 54 
  
2 
Vermote48 1986 3 neurology MS 83 3.6 
      Zorro49 2009 37 neurosurgery 729 5 10 27 54 0 
 
11 
TOTAL 905 
  
317 486 49 65 
 
72 
*mean±sd is reported if available. 
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Table 3 Pharmacological trials reporting outcomes for patients with multiple sclerosis and 
trigeminal neuralgia      
1st 
Author 
Year  
Study 
duratio
n 
(Month) 
Drug  
Daily 
dosag
e 
mg/da
y 
No. 
patient
s  
Mean/media
n age Type of MS 
Duratio
n MS 
years 
Duratio
n TN 
years 
Mean/Media
n follow up 
months 
Outcom
e 
measure  
Overall 
impact  
No 
side 
effect
s 
Side effects 
Espir 
1970  50 48 
Carbamazepin
e 
760 5 NR NR NR 3.33 NR 
good/ 
poor pain 
relief 
4 good 
response , 2 
recurred  
1 NR 
Leandri 
2000 * 
52
 
2 Carbamazepin
e 
400-
800 18 51.5 NR 14.7 7.1  
0-4 
intensity 
activity 
evoked 
pain pt 
score  
post treat 
mean 1.7 16 Drowsiness 
  
Lamotrigine 75-400 
       
post treat 
mean 0.2 1 skin rash  
Lunardi  
1997 * 
54
 
6 Lamotrigine 25-400 
    
NR 
 
0-4 
intensity 
activity 
evoked 
pain 
patient 
and 
clinician 
score  
   
  
idiopathic TN 
 
15 68 NR 
  
5.5 
 
baseline 
mean score 
2  post 
treatment 11 
patients 
score 0 
1 Skin rash 
  
TNMS 
 
5 54 NR 2.5 
 
5 
 
baseline 
mean score 
2 post 
treatement 
score 0  
NR 
 
Khan 
1998 55 1 Gabapentin  
900-
2400 7 39.2 NR 9.7 3.6 12 
complete 
or partial 
relief 
6 complete 
pain relief, 1 
partial  
NR 
 
Solaro 
1998 * 
56
 
3 Gabapentin 600-1200 6 NR NR NR NR 5.6 
0-4 
intensity 
activity 
evoked 
pain pt 
and 
clinician 
score  
5 complete 
pain relief, 1 
partial 
2 tiredness, nausea  
Zvartau
-Hind 
2000 53 
9 Topiramate 50-300 6 36.6 NR 7.5 3.8 6-9 
complete 
, partial 
pain 
relief 
5  pain free  0 NR 
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Solaro 
2001* 57 NR Topiramate  200 2 58, 39 NR 32, 9  15,1  
0-4 
intensity 
activity 
evoked 
pain pt 
score 
baseline 
mean score  
2 post 
treatment 
score 0  
0 0 
Solaro  
2000 * 
16
 
2 Carbamazepin
e & 400 6 52 3 RR 8.8 3.36 NR 
0-4 
intensity 
activity 
evoked 
pain pt 
score  
baseline 
mean score 
1.5 post 
treatment  
0.2 
0 0 
  
Gabapentin 850 
  
3 SP 
       
  
Lamotrigine & 150 5 49.6 1 RR 6.4 2.89 NR 
0-4 
intensity 
activity 
evoked 
pain pt 
score  
baseline 
mean score 
1.8 post 
treatment 
score 0 
1 Mild imbalance 
  
Gabapentin 780 
  
4 SP 
       
Reder  
1995 6 NR Misoprostol 
0.3-
0.8ug    7 47 
4 RR,1CP, 2 
unknown 23 NR NR 
complete 
, partial 
or no 
pain 
relief 
4  complete 
pain relief , 
2 partial ,1 
nil  
NR mild not specified 
DMKG 
2003 51 1 Misoprostol 
0.6ug  
for 14 
days  
18 50.3 
8 
RR,3PP,5SP,
2 unknown 
12.2 1.27 1 
50% 
decrease 
number 
attacks & 
pain 
intensity  
9 effective 
pain relief , 
5 no relief ,  
4  
spontaneou
s remission 
,4 
recurrences   
4 Severe menorrhagia withdrew trial 
, diarrhoea, GI discomfort  
* authors at same 
institution              
NR not reported RR remitting remission, PP primary progressive, SP secondary progressive  CP 
chronic progressive         
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Table  4 Details of surgical 
pwTNMS  
        
           
 1st Author Year  TN 
Diagnostic  
Criteria 
 Affected 
Side 
 TN 
Division 
Outcome Measurement  Operative 
Technique 
KM 
use 
Comments  
   
Left Right Bilatera
l 
     
 
MVD 
         
1 Broggi  2004 10 NR 12 20 3 19 one 
division  
Excellent- pain relief w/o 
meds; Good- pain relief w/ 
intermittent low dose 
meds: cbz<600mg; Fair- 
pain relief with high dose 
meds cbz > 600mg; Poor- 
drug-resistant recurrence 
or intolerance to anti-
neuralgic therapy EDSS 
score done 
Teflon or fibrillar 
oxidised 
cellulose Veins 
coagulated      
Yes Independent 
Evaluator 
2 Sandell  2010 7 Burchiel 
Classification
* 
11 8 0 4 one 
division  
Visual analgue scale VAS 
pain relief - no pain and 
no medication significant 
improvement when pain 
score 0-3 
 No  
 
PSR 
         
3 Abhinav 2012 8 Typical and 
Atypical with 
no definition 
9 14 0 NR no or mild pain, moderate 
, no relief 
PSR: 5 MS had 
decompression  
No  
           
 
GKS 
         
4 Zorro 2009 48 NR   11 13 one 
division  
BNI majority: 1 
isocentre 4mm 
median dose 
80GY 
Yes Independent 
Assessor 
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5 Mathieu  2012 37 Typical 
episodic; 
Atypical 
background 
pain; 
Constant 
pain 
12 15  13 one 
division  
BNI 80-90 GY one 
isocentre  
No  Independent 
Observer 
6 Weller  2013 63 NR  NR  18 one 
division  
BNI: pre and post  
treatment failure if BNI IV 
or V 
90Gy using one 
4mm collimeter  
Yes Telephone 
Interview 
7 Mohammad-
Mohammadi 2013 9 
Typical TN , 
Atypical 
constant pain 
between 
  4 54 one 
division  
NR 75-86 Gy one 
isocentre 
Yes  
8 Tuleasca 2014 46 Type 1 and 
type 11 as 
per Burchiel 
classification  
22 21 2 22 one 
division 
BNI, Burchiel, Regis  4 mm single 
isocentre 
median dose 
85Gy 
Yes  Independent 
Observer 
Telephone 
Interview 
9 Taich 2016 59 NR NR NR NR NR BNI 4mm iso dose 
85-90 GY  
No   
           
 
PRGR 
         
10 Dieckmann 1987 60 NR NR NR NR NR NR cisternography  
0.15-0.4 ml 
glycerol  
No Data not 
separated 
11 Linderoth  1989 34 NR   4 NR pain free, incomplete pain 
relief with meds  
cisternography 
0.20- 0.30ml 
glycerol  
No  
12 Kondziolka 1994 65 NR   7 21 one 
division 
Excellent- no meds , good 
pain control with meds, 
Poor- inadequate control 
with meds 
cisternography 
0.15- 0.30ml 
glycerol 
No  
13 Pickett  2005 41 NR 33 16 4 21 one 
division 
complete pain relief with 
or without meds; partial 
pain reduction- anything 
less than pre-op 
no 
cisternography 
0.05- - 0.4ml till 
mild sensory 
loss  
Yes Telephone 
Follow up 
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14 Mathieu 2012 37 Typical and 
Atypical 
constant 
9 9  9 one 
division 
BNI cisternography, 
0.6ml ( 0.4-1.0) 
glycerol 
No  
15 Mallory 2012 66 Classical 
atypical if 
constant pain 
24 43  29 one 
division 
Excellent- pt remained 
pain free ˃ 1 mth, no 
meds; Good- pain free > 1 
month with meds; Poor- 
no relief or return within a 
month 
cisternography, 
0.4ml ( 0.25-0,6) 
glycerol  
Yes   
16 Mohammad-
Mohammadi  2013 9 
Typical TN , 
Atypical 
constant pain 
between 
NR NR NR NR NR 0.5 ml glycerol Yes   
17 Bender  2013 24 provided 
some data 
  3 6 one 
division 
Pain relief no meds, pain 
relief with meds; Partial 
relief, no relief without 
meds  
fluroscopy only 
0.3-0.4ml 
glycerol  
Yes  
           
 
BC 
         
18 Montano 2012 38 Typical/ 
Atypical 
 NR  8 one 
division 
BNI time of 
compression 2-
12 min pear -
like 6 elliptical  
Yes KM divided 
into 
prognostic 
factors, no 
overall KM 
19 Mohammad-
Mohammadi 2013 9 
Typical TN , 
Atypical 
constant pain 
between  
 NR  NR NR  compression 
time 1 minute  
for repeat added 
30 sec  
Yes  
20 Martin  2015 36 NR  NR  NR Excellent- Pain free, off 
meds; Satisfactory  
occasional pain + or - 
meds, poor dyseasthesia; 
Recurrence 
 
 
 
NR No  
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21 Teo 2015 67 NR  NR  NR Pain relief no meds, Occ 
pain  with  or without 
meds; Poor, moderate or 
severe dyseasthesia; Fail- 
no relief, pain recurrence  
Pear shape 
0.5ml  
compression 3-
4 mins  
Yes  
           
 
RFT 
         
22 Brisman 1987  27 NR  NR  NR NR NR Yes  
23 Fraioli 1989 69 NR  NR  NR NR Sweet 
technique nil 
else reported  
No  
24 Kanpolat  2000 12 NR   1 8 one 
division 
complete pain free no 
meds, partial  some meds  
60-70C for one 
minute  five 
times varied till 
sensory change 
Yes  
25 Berk 2003 25 classical and 
provided 
criteria  
4 6 3 12 one 
division 
NR    
           
 
RFT GR 
         
26 Bender 2013 24 NR   6 23 one 
division 
Pain relief no meds, pain 
relief with meds; Partial 
relief, no relief without  
meds  
fluroscopy only 
0.3-0.4ml 
glycerol  60C  
for 60 sec  
Yes  
           
Outcome measures: EDSS -Expanded Disability Status Scale ;BNI- Barrow Neurological Institute  1- no pain II occasional pain not requiring medication,III 
some pain controlled with medication ,IV some pain ,  not controlled by medication, V severe pain; meds - medication; Regis 1 no TN no meds,IIno pain with 
meds,IIIa pain improved with meds, IIIb pain improved on meds, III pain frequency reduction >90%, IV pain frequency reduction 50-90%, V no pain reduction, 
VI pain worsening  Burchiel I pain free no meds, II pain free on meds,IIIa pain improved no meds, IIIB pain improved on meds, IV pain not improved  
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Table 5 Results from surgical interventions for patients with TN 
and MS  
         
  
1st author 
year  
Study 
durati
on 
yrs 
No. 
patie
nts  
Mean/me
dian age 
yrs 
Mean/Me
dian 
follow up  
months 
(range) 
Lost 
to 
follow 
up 
AP
R 
rate 
% 
Probability of a 
recurrence at yearly 
intervals  
Recurre
nce 
rate% 
median 
time to 
recurrenc
e months 
Complications 
                
1 2 3 4 5 
      
 
MVD 
              
1 Broggi 2004 
10
 
8 35 52 44 (6-108) 2 100 45 42 38 38 30 39 13.5 permanent facial palsy 
1 
2 Sandell  
2010 7 
8 19 53 65 4 47      NR NR bacterial meningitis1, 
facial numbness 2, 
dizziness1, impaired 
hearing 2 
Total  Average 
MVD 
8 54 105 54.5 6 73.5 45 42 38 38 30 39 13.5  
 
PSR 
              
3 Abhinav 
2012 8 
12 23 50 33 (24-80) NR 87      21.7  numbness 22, AD1 
 
SRS 
              
4 Zorro 2009 
48
 
12 37 59   0 97 82.
6 
N
R 
73.
9 
N
R 
54 37.8 74.5 facial numbness 2 
5 Mathieu 
2012 37 
5 27 59 39 NR 81.4 N
R 
N
R 
N
R 
N
R 
N
R 
51.9 26.5 sensory loss and 
paraesthesia 6 
6 Weller 2013 
63
 
8 35 62 39 (3-97) 2 82 57 57 52 52 52 40.7 9.6 facial disturbance 13 
7 Mohammad
- 
Mohammadi  
2013  9 
16 24 NR 67 (2-192) NR 50 27 18 14 N
R 
5 67 23 0 
8 Tuleasca 
2014 46 
18 43 NR 53.8 (12-
157.1) 
2 90.7 71.
8 
53.
6 
43.
1 
N
R 
38 61.5 16 numbness 4 
9 Taich 2016 
59
 
12 14 NR 24 NR 92 N
R 
N
R 
N
R 
N
R 
N
R 
NR NR NR as mixed series 
Total Average 
SRS 
12.1 180 60.1 46.7 4 83.6 63.
2 
46.
4 
48.
5 
52 40.
1 
51.1 30.4 
 
 
PGR 
              
10 Dieckmann 
1987 60 
5.5 21 NR 24 13 88.2 N
R 
N
R 
N
R 
N
R 
N
R 
40 NR Not  separated 
11 Linderoth 11 23 NR 43.5 0 91 64 N N N 16 61 26 NR 
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1989 34 R R R 
12 Kondziolka  
1994 65 
11 56 35 36 (6-122) 24 59 N
R 
N
R 
N
R 
N
R 
N
R 
30 17 herpes simplex10, 
severe numbness 1, 
moderate sensory 
change 5, mild sensory 
change 12  
13 Pickett 2005 
41
 
19 53 55 81 (2-151) NR 91 50 40 38 28 25 59 17 dec corneal reflex 7; no 
corneal reflex 2, 
parasthesia 3 ; herpes 
simplex 1, meningitis 2, 
masticatory weakness 4  
14 Mathieu 
2012 37 
5 18 56.5 38 NR 100 N
R 
N
R 
N
R 
N
R 
N
R 
38.9 17 sensory changes 11, no  
corneal reflex 2 
15 Mallory 
2012 66 
13 67 60.5 28.3 NR 75 46 38 30 25 20 54 NR numbness 35, no 
corneal reflex 2 
16 Mohammad
- 
Mohammadi 
2013 9 
16 39 NR NR NR 70 45 35 29 N
R 
15 69 28 no corneal reflex 1, 
temporary numbness 4, 
severe numbness 1 
17 Bender 
2013 24  
12 22 53 25 2 68 60 21 21 18 18 87 20 no corneal reflex 2, mild 
sensory change 5, 
herpes simplex 2 
Total Average 
PGR 
12.8 299 51.4 42.1 39 77.3 50.
4 
35.
9 
31.
0 
25.
0 
19.
7 
53.4 20.3 
 
 
BC 
              
18 Montano 
2012 38 
11 21 52 51.57 NR 81 16 10 8 6 3 57 15 mild hypoesthesia 2 
19 Mohammad
-
Mohammadi 
2013 9 
16 19 NR NR NR 95 71 57 36  21 61 29 temp numbness 11, 
severe numbness 1, 
dec corneal reflex 1, 
masticatory weakness 2 
20 Martin. 2015 
36
 
10 17 58.5 43.1 0 82 N
R 
11 N
R 
N
R 
N
R 
86 15.5 meningitis 2, 
dysesthesia 2,cheek 
haemtoma 3 
21 Teo 2015 67 10 17 NR 28.7 NR 88 63 27 21 N
R 
N
R 
NR 15.5 Not separated 
Total Average 
BC 
11.8 74 54.9 41.9 0 86.4 48.
4 
26.
2 
21.
2 
6 11.
6 
67.0 18.8 
 
 
RFT 
              
22 Brisman 
1987 27 
10 10 50 NR NR 100 92 50 25 N
R 
N
R 
25 NR numbness 2 
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23 Fraioli 1989 
69
 
NR 18 NR 69.6 NR 100 N
R 
N
R 
N
R 
N
R 
N
R 
11 NR Analgesia 7, 
anaesthesia 11 
24 Kanpolat  
2000 12 
25 17 45 60 (6-141) 0 94.1 N
R 
N
R 
N
R 
N
R 
14 29.4 25 hyperalgesia and 
hypoesthesia 13 
25 Berk 2003 25 4 13 54 52 NR NR N
R 
N
R 
N
R 
N
R 
N
R 
50 30 numbness number not 
specified 
Total Average 
RFT 
14.4 58 49.2 61.4 0 97.8 92 50 25 
 
14 27.5 27.2 
 
 
RFT/PGR 
              
26 Bender 
2013 24  
12 46 58 25 13 72 70 50 35 20 20 64 26 no  corneal reflex 1; 
anaesthesia 1;mild 
sensory loss 
17;masticatory 
weakness 1 
 
 
 
 
Legend : APR;  acute pain relief  MVD ;microvascular decompression   PSR; partial sensory rhizotomy   SRS;  stereotactic radiosurgery  BC; balloon 
microcompression  PGR;  percutaneous glycerol rhizotomy RFT; radiofrequency thermocoagulation     AD; anaesthesia dolorosa   NR ; not reported  temp : 
temporary  dec : decreased                 
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Figure 1 Flow chart of the search process   
 
 
 
 
540 records 
identified through 
database search  
78  Full articles 
assessed for eligibility  
 
Medical therapies 
N=15 
Surgical therapies  
N=63 
Reviews  
N= 2 
Case series 
N= 10 
Systematic 
reviews  
N=2  
Case series 
included  
N=26 
467 excluded after evaluation of 
title/abstract:  non relevance , 
reviews, imaging , mechanisms, 
not in English 
Abstract only N= 20 
Unable to get full paper N=6  
35 excluded with 
reasons:  
Follow up <2years N=6 
<10 cases N=17 
Unable separate out 
pwTNMS N=9 
Low quality N=1 
Repeated data N=2 
3 excluded 
Single 
cases 
Retrieved 
from papers 
5  
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Highlights  
Ms. Ref. No.:  WNS-17-3306 
Title: A systematic review of the management of trigeminal neuralgia in patients with multiple 
sclerosis. 
 
A systematic review of the management of trigeminal neuralgia in patients with 
multiple sclerosis.   
1. First systematic review of all modalities for management of patients with trigeminal 
neuralgia and multiple sclerosis shows poor quality of data. 
2. A variety of antiepileptic drugs and misoprostol have been used in patients with TNMS 
but results are poor and significant side effects occur  
3. All surgical procedures give patients a mean of two and half years of pain relief and 
need to be repeated.  
4. More higher quality trials are required. 
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A systematic review of the management of trigeminal neuralgia in patients with 
multiple sclerosis.   
Abbreviation list  
 
AD Anaesthesia dolorosa  
APR Acute pain relief  
AED Antiepileptic drug 
BC balloon microcompression 
BNI Barrow Neurological Institute 
EDSS Expanded Disability Status Scale 
MS Multiple sclerosis 
MRI Magnetic resonance imaging  
MVD Microvascular decompression  
NR Not reported  
NVC Neurovascular compression  
PGR percutaneous glycerol rhizotomy   
PSR Partial sensory rhizotomy  
PwTNMS Patient with trigeminal neuralgia and multiple sclerosis 
SRS  stereotactic radiosurgery procedures 
RFT radiofrequency thermocoagulation 
TN Trigeminal neuralgia  
VAS Visual analogue scale  
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